Thalidomide-O-C4-COOH

Background Introduction

Thalidomide-O-C4-COOH is a specialized E3 ligase ligand-linker conjugate derived from thalidomide, a well-characterized immunomodulatory drug. This compound features a thalidomide moiety linked through a four-carbon (C4) linker terminating in a carboxylic acid (COOH) functional group. Thalidomide-based ligands have become essential in the development of targeted protein degradation technologies, such as PROTACs (Proteolysis Targeting Chimeras), due to their high affinity for the cereblon (CRBN) E3 ubiquitin ligase.

Mechanism

Thalidomide-O-C4-COOH exploits the natural binding affinity of thalidomide derivatives to the CRBN E3 ubiquitin ligase. In PROTAC strategies, this ligand-linker construct is covalently attached to a target-protein binder, forming a bifunctional molecule. The thalidomide moiety recruits the CRBN E3 ligase, while the other end binds the protein-of-interest. This brings the target protein into proximity with the cellular ubiquitination machinery, leading to its ubiquitination and selective proteasomal degradation. The four-carbon linker and carboxyl functional group provide synthetic versatility for conjugation to various target ligands, thereby facilitating the generation of diverse PROTAC molecules.

Applications

Thalidomide-O-C4-COOH is extensively used in the chemical synthesis of next-generation PROTACs and related targeted protein degradation modalities. Researchers utilize this conjugate as an E3 ligase-recruiting building block to create cell-permeable PROTACs that selectively eliminate disease-relevant proteins, including oncogenic, epigenetic, and neurodegenerative targets. Its design makes it ideal for structure-activity relationship (SAR) studies, discovery of novel therapeutics, and proof-of-concept experiments in both academic and pharmaceutical research settings focused on drug discovery and chemical biology.

The E3 Ligase Ligand-Linker Conjugate, Thalidomide-O-C4-COOH, plays a crucial role in the development of PROTACs by facilitating targeted protein degradation. This molecule offers a balanced combination of a flexible linker and a potent ligand, enhancing efficiency and specificity in protein targeting. The following provides a detailed description of this molecule.

Linker: The linker in Thalidomide-O-C4-COOH is a C4 alkyl chain, providing moderate flexibility and optimal length for effective spatial orientation between the ligand and the target protein. It is non-cleavable, ensuring stable conjugation throughout the degradation process.

Ligand: The ligand is derived from thalidomide, a well-characterized cereblon-binding moiety. Its structural characteristics include a phthalimide ring, which is crucial for binding to the E3 ubiquitin ligase complex, thereby facilitating the recruitment of the target protein for degradation.

Reactive Site: The reactive site features a carboxylic acid group, which is ideal for coupling with amine-containing target protein ligands. Recommended reaction types include amide bond formation, which is reliable and commonly used in bioconjugation techniques.

Recommended Target Protein Ligand: The compatible warhead for this conjugate is an amine-functionalized ligand, which can form a stable amide bond with the carboxylic acid group. This choice provides advantages in terms of stability and specificity, making it suitable for applications in targeted degradation studies to explore protein function and regulation in cellular systems.